# Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

> **NCT05919537** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Hummingbird Bioscience** · enrollment: 68 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer
- Pancreatic Cancer
- Locally Advanced Solid Tumor
- Metastatic Solid Tumor

## Interventions

- **DRUG:** HMBD-001
- **DRUG:** Docetaxel
- **DRUG:** Nab-paclitaxel
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT05919537
- **Lead sponsor:** Hummingbird Bioscience
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-06
- **Primary completion:** 2031-03-01
- **Final completion:** 2031-03-01
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2025-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05919537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05919537, "Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05919537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*